ÍâÏÔ×Ó²âÐò·¢ÏÖ¼±ÐÔºìϸ°û°×Ѫ²¡ÐÂÍ»±ä
¼±ÐÔºìϸ°û°×Ѫ²¡£¨AEL£©Êǰ×Ѫ²¡£¨AML£©ÑÇÐÍÖеÄÒ»ÖÖ£¬ÔÚÀÏÄêÈ˰×Ѫ²¡ÖеÄÕ¼±È½Ï¸ß¡£Ïà¶ÔÓÚÆäËûÀàÐ͵ÄAML£¬AEL²¡ÈËÓиü¼Ópoor-riskµÄϸ°ûÒÅ´«Ñ§Òì³£ºÍ²»Á¼µÄÔ¤ºó¡£ËäÈ»Õë¶ÔAELµÄÍâÏÔ×ÓÍ»±äλµã·¢ÏÖÒÑÓÐһЩ±¨µÀ¡£µ«ÊÇ£¬Õë¶ÔAELµÄÍêÕûÍ»±äÆ×·¢ÏÖ»¹Ã»ÓÐÏà¹Ø±¨µÀ¡£Ñо¿ÈËÔ±ÔËÓÃÍâÏÔ×Ó×é²âÐò¼¼Êõ£¬·¢ÏÖÁËAMLÏà¹ØµÄ¸ßƵͻ±ä»ùÒòGATA2ºÍCEBpAµÈÍ»±ä£¬ÎªÀí½â¼±ÐÔºìϸ°û°×Ѫ²¡µÄ·¢Éú·¢Õ¹¹ý³ÌÌṩÁËеÄÖ¤¾Ý¡£
Ñо¿Ë¼Â·
Ñо¿½á¹û
1.ÍâÏÔ×Ó×é²âÐòɸѡAMLÏà¹Ø¸ßƵͻ±ä
ΪÁËɸѡºÍAMLÏà¹ØµÄÌØÒìÐÔ¸ßÆµÍ»±ä£¬Ñо¿ÈËÔ±¶Ô158¸öÁÙ´²AEL²¡ÈË£¨91¸öÄÐÐÔ£¬67¸öÅ®ÐÔ£©½øÐÐÁËÏêϸµÄÁÙ´²·ÖÀࣨ37¸öMDS-AEL£¬108¸öN-AEL£¬13¸öAML-MRC£©ºÍϸ°ûÒÅ´«Ñ§ÌØÐÔ·ÖÎö¡£È»ºóÔËÓÃÈ«ÍâÏÔ×Ó²âÐò£¨ÓÉÉϺ£²®ºÀ¶þ´ú²âÐòƽ̨Ìṩ£©£¬Ñо¿ÈËÔ±¶ÔÆäÖеÄ6¸öAELÑù±¾¼°ÆäremissionÑù±¾½øÐÐÁËÌåϸ°ûÍ»±ä·ÖÎö£¬¹²·¢ÏÖÁË436¸ö°×Ѫ²¡Ïà¹ØµÄÉæ¼°µ½288¸ö»ùÒòµÄ·ÇͬÒåÍ»±ä£¨428¸ö´íÒ壬8¸öÎÞÒåÍ»±ä£©¡£ÆäÖУ¬ÓÐ45¸öÍ»±ä¶à´Î³öÏÖ£¬°üÀ¨4¸öcase³öÏÖCEBpAÍ»±ä£¬2¸öcase³öÏÖGATA2Í»±ä¡£
½ÓÏÂÀ´£¬Ñо¿ÈËÔ±ÔÚ58¸öAEL²¡ÈËÖУ¨29¸öN-AEL£¬9¸öAML-MRC£¬13¸öMDS-AEL£¬7¸öÆÕͨAEL£©½øÐÐÁËGATA2£¬CEBpA£¬NpM1ºÍFLT3-ITDµÄ18¸öÍ»±äµÄSanger²âÐòÑéÖ¤¡£½á¹ûÏÔʾ£¬ÓÐ42¸ö²¡ÈËÖÐÓÐ17¸öЯ´øÒ»¸öÍ»±ä£¬25¸öЯ´ø2¸öÍ»±ä£¬6¸öЯ´ø3¸öÍ»±ä£¬3¸öЯ´ø4¸öÍ»±ä¡£ÆäÖУ¬CEBpAÍ»±äƵÂÊΪ32.7%£¬GATA2Í»±äƵÂÊΪ22.4%£¬NpM1Í»±äƵÂÊΪ15.5%£¬SETBp1Í»±äƵÂÊΪ12.1%£¬U2AF1Í»±äƵÂÊΪ12.1%¡£ÖµµÃ×¢ÒâµÄÊÇ£¬ÔÚAML·¢ÏÖµÄÍ»±ä£¨IDH1£¬IDH2ºÍRAS£©²¢Ã»ÓÐÔÚAELÖгöÏÖ¡£
GATA2ÊÇÒ»¸öºÍÔìѪ¹¦ÄÜÏà¹ØµÄпָת¼Òò×Ó£¬ÔÚ¸ÃÑо¿Öй²ÓÐ13¸öAEL³öÏÖÍ»±ä¡£·ÖÎöÏÔʾ£¬ÕâЩͻ±äÓ°Ïì7¸ö²»Í¬µÄ°±»ùËáÇøÓò¡£ÆäÖУ¬10¸ö²¡È˵ÄÍ»±äλÓÚN-terminal ZF1,3¸ö²¡È˵ÄÍ»±äλÓÚת¼¼¤»îÇøÓò£¨Q20H£©£¬12¸ö²¡È˵ÄÍ»±äΪ´íÒåÍ»±ä£¬ÆäÖÐÓÖÓÐ9¸öλÓÚDNA-binding N-terminal zinc-fingerÇøÓò¡£
´ËÍ⣬ΪÁË̽¾¿GATA2ÓëѪҺ²¡µÄ¹ØÏµ£¬Ñо¿ÈËÔ±¶Ô253¸önon-AEL AML,40¸öÂýÐÔ¹ÇËè°×Ѫ²¡£¬55¸öBϸ°û°×Ѫ²¡ºÍ38¸öTϸ°û°×Ѫ²¡È˽øÐÐÁ˼ì²â¡£½á¹ûÏÔʾ£¬Ö»ÓÐ5.5%µÄnon-AEL AMLºÍ15%ÂýÐÔ¹ÇËè°×Ѫ²¡·¢ÉúÍ»±ä¡£Òò´Ë£¬GATA2ÊÇAELÌØÓÐµÄ¸ßÆµÍ»±ä¡£
2.GATA2 ZF1Í»±äÄ£ÐÍ·ÖÎö
ΪÁ˸ü¼ÓÉîÈëµØÀí½âGATA2Í»±ä¶Ôµ°°×ˮƽµÄÓ°Ï죬Ñо¿ÈËÔ±¶ÔAELµÄGATA2 ZF1Í»±äÄ£ÐͽøÐÐÁË·ÖÎö¡£½á¹ûÏÔʾ£¬p304£¬A318£¬L321£¬R330ÇøÓòÊÇGATA¼Ò×åµ°°×±£ÊØÇøÓò£¬¶ÔDNA-binding¹¦Äܷdz£ÖØÒª¡£¸ù¾ÝÒÑÓжÔgata3µ°°×¾§Ìå½á¹¹µÄ·¢ÏÖ£¬Ñо¿ÈËÔ±¹¹½¨ÁË3¸ögata3µ°°×¾§Ìå½á¹¹£¨pDB code 4hc9, 4hca and 4hc7B£©¡£½á¹ûÏÔʾ£¬p304, A318, L321ºÍ R330µÄÍ»±ä²Ð»ù¶¼Î»ÓÚgata2µÄµ°°×±íÃæ£¬ÊÇÖ±½ÓÓëDNA½áºÏµÄ²¿Î»¡£Òò´Ë£¬ÔÚÕâÀï·¢ÏÖµÄGATA2Í»±äÏ÷ÈõÁ˸õ°°×ÓëDNAµÄ½áºÏÄÜÁ¦¡£
3.GATA2Í»±äµÄ¹¦ÄÜÑо¿
¼ÈÈ»GATA2µÄÍ»±äÓ°ÏìÁ˵°°×ÓëDNAµÄ½áºÏÄÜÁ¦£¬ÄÇô£¬ÕâÖֱ仯¶Ôϸ°ûµÄ¹¦ÄÜÓÐʲôӰÏ죿Ñо¿ÈËÔ±ÔÚ293Tϸ°ûÖй²×ªÁËGATA-responsive reporter£¨wild typeºÍmutants£©¡£½á¹ûÏÔʾ£¬×ªÈ¾mutantsʱ£¬×ªÂ¼»îÐÔ½µµÍ¡£µ±¹²×ªWt-GATA2ºÍÍ»±äR330X-GATA2ʱ£¬Wt-GATA2ת¼»îÐÔÏÔÖø½µµÍ£¬°µÊ¾×ÅR330X-GATA2°üº¬Wt-GATA2µÄ¸ºµ÷¿Ødominant¡£µ±ÔÚСÊó¹ÇËèϸ°û32D Öйý±í´ïGATA2Í»±äʱ£¬ºìϸ°ûÏà¹Ø¿¹Ô£¬Ter-119,¦Â-globin,¦Âh1-globin±í´ïÔö¼Ó£¬Ñªºìµ°°×positivityÔö¼Ó¡£
Òò´Ë£¬¸Ã½á¹û±íÃ÷£¬GATA2Í»±äÓ°ÏìÁËѪºìϸ°ûµÄ·¢Óý¹ý³Ì¡£
Ñо¿½áÂÛ
±¾Ñо¿Í¨¹ýÍâÏÔ×Ó×é²âÐò£¬·¢ÏÖÁËAELÏà¹ØµÄÌØÒìÐÔÌåϸ°ûÍ»±ä¡£ÆäÖУ¬¶ÔGATA2µÄ´óÑù±¾ÑéÖ¤¼°²»Í¬ÀàÐͰ×Ѫ²¡Ñù±¾ÑéÖ¤£¬±íÃ÷ÆäʵAELËùÌØÓÐµÄ¸ßÆµÍ»±ä¡£´ËÍ⣬ͨ¹ýÍ»±äתȾµÄϸ°ûʵÑéÑо¿±íÃ÷£¬GATA2µÄÍ»±äÓ°ÏìÁ¦ºìϸ°ûµÄ·¢Óý¹ý³Ì¡£¸ÃÑо¿ÎªÀí½â¼±ÐÔºìϸ°û°×Ѫ²¡µÄ·¢²¡»úÖÆÌṩÁËеÄÖ¤¾Ý¡£
ÔÎijö´¦£ºping N, Sun A, Song Y, et al. Exome sequencing identifies highly recurrent somatic GATA2 and CEBpA mutations in acute erythroid leukemia. Leukemia. 2016